The effect of intravitreal cidofovir injection on end-stage glaucoma in dogs: a retrospective study of 153 eyes

Hyelin Kim Department of Veterinary Clinical Sciences, College of Veterinary Medicine and Research Institute for Veterinary Science, Seoul National University, Gwanak-gu, Seoul, Republic of Korea

Search for other papers by Hyelin Kim in
Current site
Google Scholar
PubMed
Close
 DVM, MS https://orcid.org/0000-0002-4282-2884
,
Seonmi Kang Department of Veterinary Clinical Sciences, College of Veterinary Medicine and Research Institute for Veterinary Science, Seoul National University, Gwanak-gu, Seoul, Republic of Korea

Search for other papers by Seonmi Kang in
Current site
Google Scholar
PubMed
Close
 DVM, PhD, DAiCVO
,
Dajeong Jeong Department of Veterinary Clinical Sciences, College of Veterinary Medicine and Research Institute for Veterinary Science, Seoul National University, Gwanak-gu, Seoul, Republic of Korea

Search for other papers by Dajeong Jeong in
Current site
Google Scholar
PubMed
Close
 DVM
,
Junyeong Ahn Department of Veterinary Clinical Sciences, College of Veterinary Medicine and Research Institute for Veterinary Science, Seoul National University, Gwanak-gu, Seoul, Republic of Korea

Search for other papers by Junyeong Ahn in
Current site
Google Scholar
PubMed
Close
 DVM, MS
, and
Kangmoon Seo Department of Veterinary Clinical Sciences, College of Veterinary Medicine and Research Institute for Veterinary Science, Seoul National University, Gwanak-gu, Seoul, Republic of Korea

Search for other papers by Kangmoon Seo in
Current site
Google Scholar
PubMed
Close
 DVM, PhD, DAiCVO https://orcid.org/0000-0001-6645-7116

Click on author name to view affiliation information

Abstract

OBJECTIVE

To evaluate the long-term efficacy, prognostic factors, and complications of intravitreal cidofovir injection in dogs with end-stage glaucoma.

ANIMALS

130 client-owned dogs.

METHODS

Medical records of dogs that underwent intravitreal cidofovir injections were reviewed. A minimum follow-up period of 6 months was required as the inclusion criterion. Signalment, type of glaucoma, preinjection intraocular pressure (IOP), types of applied glaucoma eye drop, coexisting ocular diseases, outcomes, and complications were recorded. Success was defined as IOP of ≤ 25 mm Hg at the 2-week recheck that remained to the 6-month recheck.

RESULTS

The overall success rate of intravitreal cidofovir injection was 91.5% (140/153). The success rate of a single injection was 69.3% (106/153), of a second injection was 59.5% (25/42), of a third injection was 42.9% (6/14), of a fourth injection was 33.3% (2/6), and of a fifth injection was 50.0% (1/2). Intraocular pressures at 6 months after injection were relatively higher when the injection was repeated, fewer types of glaucoma eye drop were applied prior to the injection, and cataract stages were advanced at the time of injection (P < .05). The most common complications were phthisis bulbi (42.5%), cataract progression (30.1%), and intraocular hemorrhage (16.3%). Six eyes were enucleated, and 3 were enucleated due to corneal perforation.

CLINICAL RELEVANCE

Intravitreal cidofovir injection had a high long-term success rate in lowering IOP in dogs with end-stage glaucoma.

Abstract

OBJECTIVE

To evaluate the long-term efficacy, prognostic factors, and complications of intravitreal cidofovir injection in dogs with end-stage glaucoma.

ANIMALS

130 client-owned dogs.

METHODS

Medical records of dogs that underwent intravitreal cidofovir injections were reviewed. A minimum follow-up period of 6 months was required as the inclusion criterion. Signalment, type of glaucoma, preinjection intraocular pressure (IOP), types of applied glaucoma eye drop, coexisting ocular diseases, outcomes, and complications were recorded. Success was defined as IOP of ≤ 25 mm Hg at the 2-week recheck that remained to the 6-month recheck.

RESULTS

The overall success rate of intravitreal cidofovir injection was 91.5% (140/153). The success rate of a single injection was 69.3% (106/153), of a second injection was 59.5% (25/42), of a third injection was 42.9% (6/14), of a fourth injection was 33.3% (2/6), and of a fifth injection was 50.0% (1/2). Intraocular pressures at 6 months after injection were relatively higher when the injection was repeated, fewer types of glaucoma eye drop were applied prior to the injection, and cataract stages were advanced at the time of injection (P < .05). The most common complications were phthisis bulbi (42.5%), cataract progression (30.1%), and intraocular hemorrhage (16.3%). Six eyes were enucleated, and 3 were enucleated due to corneal perforation.

CLINICAL RELEVANCE

Intravitreal cidofovir injection had a high long-term success rate in lowering IOP in dogs with end-stage glaucoma.

All Time Past Year Past 30 Days
Abstract Views 396 396 237
Full Text Views 398 398 363
PDF Downloads 398 398 353
Advertisement